Suppr超能文献

通过计算机模拟和体外实验相结合的策略发现一种有效的RET特异性非小细胞肺癌候选药物

Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer-A Combined In Silico and In Vitro Strategy.

作者信息

Ramesh Priyanka, Shin Woong-Hee, Veerappapillai Shanthi

机构信息

Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore 632014, India.

Department of Chemical Science Education, College of Education, Sunchon National University, Suncheon 57922, Korea.

出版信息

Pharmaceutics. 2021 Oct 24;13(11):1775. doi: 10.3390/pharmaceutics13111775.

Abstract

Rearranged during transfection (RET) is a tyrosine kinase oncogenic receptor, activated in several cancers including non-small-cell lung cancer (NSCLC). Multiple kinase inhibitors vandetanib and cabozantinib are commonly used in the treatment of RET-positive NSCLC. However, specificity, toxicity, and reduced efficacy limit the usage of multiple kinase inhibitors in targeting RET protein. Thus, in the present investigation, we aimed to figure out novel and potent candidates for the inhibition of RET protein using combined in silico and in vitro strategies. In the present study, screening of 11,808 compounds from the DrugBank repository was accomplished by different hypotheses such as pharmacophore, e-pharmacophore, and receptor cavity-based models in the initial stage. The results from the different hypotheses were then integrated to eliminate the false positive prediction. The inhibitory activities of the screened compounds were tested by the glide docking algorithm. Moreover, RF score, Tanimoto coefficient, prime-MM/GBSA, and density functional theory calculations were utilized to re-score the binding free energy of the docked complexes with high precision. This procedure resulted in three lead molecules, namely DB07194, DB03496, and DB11982, against the RET protein. The screened lead molecules together with reference compounds were then subjected to a long molecular dynamics simulation with a 200 ns time duration to validate the inhibitory activity. Further analysis of compounds using MM-PBSA and mutation studies resulted in the identification of potent compound DB07194. In essence, a cell viability assay with RET-specific lung cancer cell line LC-2/ad was also carried out to confirm the in vitro biological activity of the resultant compound, DB07194. Indeed, the results from our study conclude that DB07194 can be effectively translated for this new therapeutic purpose, in contrast to the properties for which it was originally designed and synthesized.

摘要

转染重排(RET)是一种酪氨酸激酶致癌受体,在包括非小细胞肺癌(NSCLC)在内的多种癌症中被激活。多种激酶抑制剂凡德他尼和卡博替尼常用于治疗RET阳性非小细胞肺癌。然而,特异性、毒性和疗效降低限制了多种激酶抑制剂在靶向RET蛋白中的应用。因此,在本研究中,我们旨在通过计算机模拟和体外实验相结合的策略,找出抑制RET蛋白的新型有效候选物。在本研究中,最初通过不同的假设,如药效团、电子药效团和基于受体腔的模型,对DrugBank数据库中的11808种化合物进行了筛选。然后整合不同假设的结果以消除假阳性预测。通过Glide对接算法测试筛选出的化合物的抑制活性。此外,利用RF评分、Tanimoto系数、Prime-MM/GBSA和密度泛函理论计算对对接复合物的结合自由能进行高精度重新评分。这一过程产生了三种针对RET蛋白的先导分子,即DB07194、DB03496和DB11982。然后将筛选出的先导分子与参考化合物一起进行持续200 ns的长时间分子动力学模拟,以验证其抑制活性。使用MM-PBSA对化合物进行进一步分析和突变研究,确定了强效化合物DB07194。实际上,还使用RET特异性肺癌细胞系LC-2/ad进行了细胞活力测定,以确认所得化合物DB07194的体外生物活性。确实,我们的研究结果表明,与最初设计和合成DB07194的性质相比,它可以有效地用于这一新的治疗目的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e207/8619101/e6aa0ae5c137/pharmaceutics-13-01775-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验